74 related articles for article (PubMed ID: 20153646)
1. Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells.
Choi SJ; Moon MJ; Lee SD; Choi SU; Han SY; Kim YC
Bioorg Med Chem Lett; 2010 Mar; 20(6):2033-7. PubMed ID: 20153646
[TBL] [Abstract][Full Text] [Related]
2. ATRA can enhance apoptosis that is induced by Flt3 tyrosine kinase inhibition in Flt3-ITD positive cells.
Scholl S; Müller R; Clement JH; Loncarevic IF; Böhmer FD; Höffken K
Leuk Res; 2006 May; 30(5):633-42. PubMed ID: 16473406
[TBL] [Abstract][Full Text] [Related]
3. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
Nishioka C; Ikezoe T; Yang J; Takeuchi S; Koeffler HP; Yokoyama A
Leuk Res; 2008 Sep; 32(9):1382-92. PubMed ID: 18394702
[TBL] [Abstract][Full Text] [Related]
4. Discovery of indirubin-3'-aminooxy-acetamide derivatives as potent and selective FLT3/D835Y mutant kinase inhibitors for acute myeloid leukemia.
Lee JH; Shin JE; Kim W; Jeong P; Kim MJ; Oh SJ; Lee HJ; Park HW; Han SY; Kim YC
Eur J Med Chem; 2022 Jul; 237():114356. PubMed ID: 35489222
[TBL] [Abstract][Full Text] [Related]
5. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
[TBL] [Abstract][Full Text] [Related]
6. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of novel indirubin derivatives in rat tumor model.
Kim SA; Kim YC; Kim SW; Lee SH; Min JJ; Ahn SG; Yoon JH
Clin Cancer Res; 2007 Jan; 13(1):253-9. PubMed ID: 17200363
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells.
Marko D; Schätzle S; Friedel A; Genzlinger A; Zankl H; Meijer L; Eisenbrand G
Br J Cancer; 2001 Jan; 84(2):283-9. PubMed ID: 11161389
[TBL] [Abstract][Full Text] [Related]
9. FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression.
Jin G; Matsushita H; Asai S; Tsukamoto H; Ono R; Nosaka T; Yahata T; Takahashi S; Miyachi H
Biochem Biophys Res Commun; 2009 Dec; 390(3):1001-6. PubMed ID: 19853583
[TBL] [Abstract][Full Text] [Related]
10. FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells.
Li L; Piloto O; Kim KT; Ye Z; Nguyen HB; Yu X; Levis M; Cheng L; Small D
Br J Haematol; 2007 Apr; 137(1):64-75. PubMed ID: 17359372
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of FLT3 phosphorylation status and its response to drugs by flow cytometry in AML blast cells.
Grafone T; Palmisano M; Nicci C; Martelli AM; Emanuela O; Storti S; Baccarani M; Martinelli G
Hematol Oncol; 2008 Sep; 26(3):159-66. PubMed ID: 18383555
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities.
Moon MJ; Lee SK; Lee JW; Song WK; Kim SW; Kim JI; Cho C; Choi SJ; Kim YC
Bioorg Med Chem; 2006 Jan; 14(1):237-46. PubMed ID: 16182537
[TBL] [Abstract][Full Text] [Related]
13. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
Kim KT; Levis M; Small D
Br J Haematol; 2006 Sep; 134(5):500-9. PubMed ID: 16869825
[TBL] [Abstract][Full Text] [Related]
14. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation.
Rausei-Mills V; Chang KL; Gaal KK; Weiss LM; Huang Q
Am J Clin Pathol; 2008 Apr; 129(4):624-9. PubMed ID: 18343790
[TBL] [Abstract][Full Text] [Related]
15. Antineoplastic effect of a single oral dose of the novel Flt3 inhibitor KRN383 on xenografted human leukemic cells harboring Flt3-activating mutations.
Nishiyama U; Yoshino T; Ozai M; Yoshioka R; Fujisawa M; Ogasawara Y; Kitahori M; Yoshioka E; Kubo K; Komeno Y; Kurokawa M; Ogawa S; Chiba S; Osawa T; Kuwaki T; Hirai H; Miwa A
Leuk Res; 2006 Dec; 30(12):1541-6. PubMed ID: 16603240
[TBL] [Abstract][Full Text] [Related]
16. Indirubin-3'-monoxime inhibits autophosphorylation of FGFR1 and stimulates ERK1/2 activity via p38 MAPK.
Zhen Y; Sørensen V; Jin Y; Suo Z; Wiedłocha A
Oncogene; 2007 Sep; 26(44):6372-85. PubMed ID: 17533378
[TBL] [Abstract][Full Text] [Related]
17. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
[TBL] [Abstract][Full Text] [Related]
18. Induction of apoptosis by a novel indirubin-5-nitro-3'-monoxime, a CDK inhibitor, in human lung cancer cells.
Lee JW; Moon MJ; Min HY; Chung HJ; Park EJ; Park HJ; Hong JY; Kim YC; Lee SK
Bioorg Med Chem Lett; 2005 Sep; 15(17):3948-52. PubMed ID: 15993584
[TBL] [Abstract][Full Text] [Related]
19. Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest.
Damiens E; Baratte B; Marie D; Eisenbrand G; Meijer L
Oncogene; 2001 Jun; 20(29):3786-97. PubMed ID: 11439342
[TBL] [Abstract][Full Text] [Related]
20. Novel anticancer compound [trifluoromethyl-substituted pyrazole N-nucleoside] inhibits FLT3 activity to induce differentiation in acute myeloid leukemia cells.
Saleh AM; Taha MO; Aziz MA; Al-Qudah MA; AbuTayeh RF; Rizvi SA
Cancer Lett; 2016 Jun; 375(2):199-208. PubMed ID: 26916980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]